Alimera Sciences Inc (ALIM)

2.04
0.03 1.40
NASDAQ : Health Care
Prev Close 2.07
Open 2.01
Day Low/High 1.85 / 2.12
52 Wk Low/High 1.01 / 5.15
Volume 3.19M
Avg Volume 613.50K
Exchange NASDAQ
Shares Outstanding 45.10M
Market Cap 74.41M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insider Trading Alert - VLGEA, LLTC And ALIM Traded By Insiders

Insider Trading Alert - VLGEA, LLTC And ALIM Traded By Insiders

Stocks with insider trader activity include VLGEA, LLTC and ALIM

Short Interest In Alimera Sciences Makes 15% Move

Short Interest In Alimera Sciences Makes 15% Move

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 314,613 share increase in total short interest for Alimera Sciences, Inc. , to 2,422,062, an increase of 14.93% since 01/15/2016.

Short Interest In Alimera Sciences Jumps 14.2%

Short Interest In Alimera Sciences Jumps 14.2%

The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 261,657 share increase in total short interest for Alimera Sciences, Inc. , to 2,107,449, an increase of 14.18% since 12/31/2015.

Short Interest In Alimera Sciences Decreases By 17.4%

Short Interest In Alimera Sciences Decreases By 17.4%

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 387,663 share decrease in total short interest for Alimera Sciences, Inc. , to 1,845,792, a decrease of 17.36% since 12/15/2015.

Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active

Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active

The CMS reimbursement code for ILUVIEN® is expected to ease and speed insurance payments

Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression

Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression

Data presented as Late Breaking Development during Retina Subspecialty Day at AAO 2015

Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015

Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015

Dan Myers, CEO, will join leading innovators in ophthalmology to discuss ILUVIEN® and advancements in the industry

Notable Thursday Option Activity: ALIM, PGTI, ENVA

Notable Thursday Option Activity: ALIM, PGTI, ENVA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alimera Sciences, Inc. , where a total volume of 12,500 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

Alimera Sciences Strengthens Financial Position

Alimera Sciences Strengthens Financial Position

Interest only repayment period extended up to 18 months

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With ILUVIEN®

Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With ILUVIEN®

Paper highlights 28 cases in the United Kingdom and Germany

Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress

Alimera Sciences Limited Announces ILUVIEN® Study Results Presented At 15th Euretina Congress

Interim six-month data confirms ILUVIEN was well tolerated and effective in reducing retinal thickness and increasing best corrected visual acuity